¶ Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease
| Field |
Value |
| NCT Number |
NCT07271927 |
| Status |
Recruiting |
| Sponsor |
Pusan National University Yangsan Hospital |
| Phase |
Not applicable (device trial) |
| Start Date |
February 2025 |
| Completion Date |
December 2025 |
- Type: Device — Photobiomodulation (PBM)
- Description: Whole-body photobiomodulation therapy applied approximately 10 weeks (three sessions per week, once daily, 20 minutes per session)
Photobiomodulation (also known as low-level light therapy) uses red or near-infrared light to stimulate cellular processes. The proposed mechanisms in Parkinson's disease include:
- Mitochondrial enhancement: Light at specific wavelengths (typically 600-1000 nm) penetrates tissue and is absorbed by cytochrome c oxidase in mitochondria, enhancing ATP production
- Reduced oxidative stress: PBM increases activity of antioxidant enzymes and reduces reactive oxygen species
- Anti-inflammatory effects: Modulation of cytokine production and microglial activation
- Neuroprotection: Promotion of neurotrophic factor release (BDNF, GDNF) and enhancement of autophagy
- Allocation: Single-arm (all participants receive active PBM treatment)
- Primary Outcome: Change in motor and cognitive function scores
- Secondary Outcomes: Safety and tolerability assessments
- Diagnosis of Parkinson's disease
- Motor and cognitive symptoms requiring intervention
This trial represents an important non-pharmacological approach to neuroprotection in PD. Unlike drug-based therapies, photobiomodulation offers a non-invasive modality with minimal side effects. The whole-body approach may address both motor and non-motor symptoms simultaneously.
- Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease - NCT07271927
- Photobiomodulation for Parkinson's Disease - NeuroWiki